The impact of timing adjuvant therapy on disease-free survival among patients with stage iib-iiia non-small cell lung cancer receiving platinum- based treatment
Öz
Aim: We aimed to investigate the relationship between time to adjuvant therapy and disease-free survival in patients with
non-small cell lung cancer who underwent curative surgical resection and received adjuvant therapy.
Material and Methods: In our study, stage IIB-IIIA patients who underwent curative surgical resection and received adjuvant therapy between 2010 and 2020 were retrospectively evaluated. They were categorized as those who started treatment before and after 6 weeks, and the time to radiologic recurrence was calculated.
Results: A total of 89 patients were included. Adjuvant treatment was started within 6 weeks after surgery in 52 patients and after 6 weeks in 37 patients. Disease-free survival was statistically significantly lower in patients who started treatment after 6 weeks (p=0.014). In addition, ECOG performance score of 0 and starting adjuvant treatment before 6 weeks were found to be independent prognostic factors in multivariate analysis (p=0.001, p=0.045).
Conclusions: In patients with NSCLC who underwent curative resection and planned adjuvant treatment, starting treatment after 6 weeks shortened disease-free survival. According to our results, it is recommended to start treatment before 6 weeks.
Anahtar Kelimeler
Kaynakça
- Sung, H., et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2021. 71(3): p. 209-249.
- Howlader, N., et al., The effect of advances in lung-cancer treatment on population mortality. New England Journal of Medicine, 2020. 383(7): p. 640-649.
- Siegel, R.L., et al., Cancer statistics, 2021. Ca Cancer J Clin, 2021. 71(1): p. 7-33.
- Rami-Porta, R., et al., The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 2015. 10(7): p. 990-1003.
- Pignon, J.-P., et al., Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group, in Database of Abstracts of Reviews of Effects (DARE): Quality-Assessed Reviews [Internet]. 2008, Centre for Reviews and Dissemination (UK).
- Pisters, K.M., et al., Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non–small-cell lung cancer guideline. Journal of clinical oncology, 2007. 25(34): p. 5506-5518.
- Network, N.C.C., Non-Small Cell Lung Cancer (version 2.2020) https://www. nccn. org/professionals/physician_gls/pdf/nscl. pdf. Accessed January, 2020. 18.
- Winton, T., et al., Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer. New England Journal of Medicine, 2005. 352(25): p. 2589-2597.
- Douillard, J.-Y., et al., Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. The lancet oncology, 2006. 7(9): p. 719-727.
- Kozower, B.D., et al., STS database risk models: predictors of mortality and major morbidity for lung cancer resection. The Annals of thoracic surgery, 2010. 90(3): p. 875-883.
- Teh, E., et al., What is the extent of the advantage of video- assisted thoracoscopic surgical resection over thoracotomy in terms of delivery of adjuvant chemotherapy following non- small-cell lung cancer resection? Interactive cardiovascular and thoracic surgery, 2014. 19(4): p. 656-660.
- Nachiappan, S., et al., The impact of adjuvant chemotherapy timing on overall survival following colorectal cancer resection. European Journal of Surgical Oncology (EJSO), 2015. 41(12): p. 1636-1644.
- Chavez-MacGregor, M., et al., Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA oncology, 2016. 2(3): p. 322-329.
- Irie, M., et al., Risk factors for short-term outcomes after thoracoscopic lobectomy for lung cancer. European Respiratory Journal, 2016. 48(2): p. 495-503.
- Postmus, P., et al., Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, 2017. 28: p. iv1-iv21.
- Szejniuk, W.M., et al., Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose- intensity and treatment delay. Cancer Treatment and Research Communications, 2021. 27: p. 100318.
- Ramsden, K., J. Laskin, and C. Ho, Adjuvant chemotherapy in resected stage II non-small cell lung cancer: evaluating the impact of dose intensity and time to treatment. Clinical Oncology, 2015. 27(7): p. 394-400.
- Booth, C.M., et al., Time to adjuvant chemotherapy and survival in non–small cell lung cancer: A population‐based study. Cancer, 2013. 119(6): p. 1243-1250.
- Salazar, M.C., et al., Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA oncology, 2017. 3(5): p. 610-619.
- Wang, B.-Y., et al., Impact on survival on interval between surgery and adjuvant chemotherapy in completely resected stage IB-IIIA lung cancer. PloS one, 2016. 11(11): p. e0163809.
Adjuvant platin bazlı tedavi verilen evre ııb-ıııa küçük hücreli dışı akciğer kanseri hastalarında adjuvant tedaviye kadar geçen sürenin hastalıksız sağkalıma etkisi
Öz
Amaç: küratif cerrahi rezeksiyon geçiren ve adjuvan tedavi verilen küçük hücreli dışı akciğer kanseri hastalarında tedaviye kadar geçen sürenin hastalıksız sağ kalımla ilişkisi
Gereç ve yöntemler: Çalışmamıza 2010-2020 yılları arasında küratif cerrahi rezeksiyon geçirmiş adjuvan tedavi alan evre IIB-IIIA hastalar alındı. Tedaviye 6 haftadan önce ve sonra başlayanlar olarak kategorize edilip radyolojik nükse kadar geçen zaman hesaplandı.
Bulgular:Toplam 89 hasta alındı. 52 hastaya tedavş 6 haftadan önce başlanmış 37 hastaya ise 6 haftdan sonra başlamış. Tedaviye 6 haftadan sonra başlanan hastalarda hastalıksız sağ kalım istatistiksel olarak anlamlı derece de daha düşüktü.
Sonuçlar: küratif rezeksiyon uygulanan adjuvan tedavi verilen küçük hücreli dışı akciğer kanseri hastalarında tedaviye 6 haftadan sonra başlamak hastalıksız sağ kalımı kısaltmıştır. Tedaviye mümkünse 6 haftadan önce başlanmalıdır
Anahtar Kelimeler
Destekleyen Kurum
destekleyen kurum yok
Kaynakça
- Sung, H., et al., Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2021. 71(3): p. 209-249.
- Howlader, N., et al., The effect of advances in lung-cancer treatment on population mortality. New England Journal of Medicine, 2020. 383(7): p. 640-649.
- Siegel, R.L., et al., Cancer statistics, 2021. Ca Cancer J Clin, 2021. 71(1): p. 7-33.
- Rami-Porta, R., et al., The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 2015. 10(7): p. 990-1003.
- Pignon, J.-P., et al., Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group, in Database of Abstracts of Reviews of Effects (DARE): Quality-Assessed Reviews [Internet]. 2008, Centre for Reviews and Dissemination (UK).
- Pisters, K.M., et al., Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non–small-cell lung cancer guideline. Journal of clinical oncology, 2007. 25(34): p. 5506-5518.
- Network, N.C.C., Non-Small Cell Lung Cancer (version 2.2020) https://www. nccn. org/professionals/physician_gls/pdf/nscl. pdf. Accessed January, 2020. 18.
- Winton, T., et al., Vinorelbine plus cisplatin vs. observation in resected non–small-cell lung cancer. New England Journal of Medicine, 2005. 352(25): p. 2589-2597.
- Douillard, J.-Y., et al., Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. The lancet oncology, 2006. 7(9): p. 719-727.
- Kozower, B.D., et al., STS database risk models: predictors of mortality and major morbidity for lung cancer resection. The Annals of thoracic surgery, 2010. 90(3): p. 875-883.
- Teh, E., et al., What is the extent of the advantage of video- assisted thoracoscopic surgical resection over thoracotomy in terms of delivery of adjuvant chemotherapy following non- small-cell lung cancer resection? Interactive cardiovascular and thoracic surgery, 2014. 19(4): p. 656-660.
- Nachiappan, S., et al., The impact of adjuvant chemotherapy timing on overall survival following colorectal cancer resection. European Journal of Surgical Oncology (EJSO), 2015. 41(12): p. 1636-1644.
- Chavez-MacGregor, M., et al., Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA oncology, 2016. 2(3): p. 322-329.
- Irie, M., et al., Risk factors for short-term outcomes after thoracoscopic lobectomy for lung cancer. European Respiratory Journal, 2016. 48(2): p. 495-503.
- Postmus, P., et al., Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, 2017. 28: p. iv1-iv21.
- Szejniuk, W.M., et al., Adjuvant platinum-based chemotherapy in non-small cell lung cancer: The role of relative dose- intensity and treatment delay. Cancer Treatment and Research Communications, 2021. 27: p. 100318.
- Ramsden, K., J. Laskin, and C. Ho, Adjuvant chemotherapy in resected stage II non-small cell lung cancer: evaluating the impact of dose intensity and time to treatment. Clinical Oncology, 2015. 27(7): p. 394-400.
- Booth, C.M., et al., Time to adjuvant chemotherapy and survival in non–small cell lung cancer: A population‐based study. Cancer, 2013. 119(6): p. 1243-1250.
- Salazar, M.C., et al., Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA oncology, 2017. 3(5): p. 610-619.
- Wang, B.-Y., et al., Impact on survival on interval between surgery and adjuvant chemotherapy in completely resected stage IB-IIIA lung cancer. PloS one, 2016. 11(11): p. e0163809.
Ayrıntılar
| Birincil Dil | Türkçe |
|---|---|
| Konular | Katı Tümörler |
| Bölüm | Araştırma Makalesi |
| Yazarlar | |
| Yayımlanma Tarihi | 30 Eylül 2023 |
| Yayımlandığı Sayı | Yıl 2023 Cilt: 14 Sayı: 3 |
Kaynak Göster
e-ISSN: 2149-8296
The content of this site is intended for health care professionals. All the published articles are distributed under the terms of
Creative Commons Attribution Licence,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.